Healios K.K Gestione

Gestione criteri di controllo 2/4

Healios K.K Il CEO è Hardy Kagimoto, nominato in Feb2012, ha un mandato di 12.75 anni. possiede direttamente 31.88% delle azioni della società, per un valore di ¥ 5.63B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.8 anni e 6.8 anni.

Informazioni chiave

Hardy Kagimoto

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	12.8yrs
Proprietà del CEO	31.9%
Durata media del management	8.8yrs
Durata media del Consiglio di amministrazione	6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Healios K.K (TSE:4593) Using Too Much Debt?

May 31

AMMINISTRATORE DELEGATO

Hardy Kagimoto (48 yo)

12.8yrs

Mandato

Dr. Tadahisa S. Kagimoto, also known as Hardy, MD, serves as Chairman, Chief Executive Officer and President of Aqumen Biopharmaceuticals, K.K. He served as Director of Athersys, Inc. since June 18, 2018 u...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Tadahisa S. Kagimoto	Chairman & CEO	12.8yrs	Nessun dato	31.88% ¥ 5.6b
Richard P. Kincaid	CFO, Executive Officer & Internal Director	5.3yrs	Nessun dato	0.21% ¥ 36.7m
Masanori Sawada	Executive VP	9.7yrs	Nessun dato	Nessun dato
Kouichi Tamura	Exec. Off.	8.8yrs	Nessun dato	Nessun dato
Yoshinari Matsuda	Managing Director	8.7yrs	Nessun dato	Nessun dato

8.8yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di 4593 è esperto e expertise (durata media dell'incarico 8.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Tadahisa S. Kagimoto	Chairman & CEO	12.8yrs	Nessun dato	31.88% ¥ 5.6b
Richard P. Kincaid	CFO, Executive Officer & Internal Director	6.8yrs	Nessun dato	0.21% ¥ 36.7m
Glenn J. Gormley	Independent Outside Director	2.8yrs	Nessun dato	Nessun dato
Seigo Kashii	Independent External Director	6.8yrs	Nessun dato	0.00022% ¥ 38.9k
Hideki Takeda	Auditor	7.8yrs	Nessun dato	0.56% ¥ 98.8m
Yuko Yogo	Independent Outside Director	2.8yrs	Nessun dato	Nessun dato

6.8yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4593 sono considerati esperti (durata media dell'incarico 6.8 anni).

Healios K.K Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Healios K.K., Annual General Meeting, Mar 27, 2024

Healios K.K. Announces Management Changes

High number of new directors

Less than half of directors are independent

Healios K.K., Annual General Meeting, Mar 25, 2022

Healios K.K. Announces Announcement of Change in Management

Recent updates

Healios K.K. Announces Agreement with the FDA on Pivotal, Global Phase 3 "REVIVE-ARDS" Clinical Trial

Price target increased by 17% to JP¥340

Healios K.K. to Report Q3, 2024 Results on Nov 13, 2024

Consensus EPS estimates upgraded to JP¥29.83 loss

Healios K.K. to Report Q2, 2024 Results on Aug 13, 2024

Is Healios K.K (TSE:4593) Using Too Much Debt?

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Healios K.K. to Report Q1, 2024 Results on May 13, 2024

Consensus revenue estimates increase by 64%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Healios K.K., Annual General Meeting, Mar 27, 2024

Healios K.K. and Procellcure Inc. Announce Start of Ards Clinical Trial in Japan

Healios K.K. announced that it expects to receive ¥2.2600715 billion in funding

Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan

Consensus EPS estimates upgraded to JP¥56.76 loss

Healios K.K. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: JP¥9.98 loss per share (vs JP¥12.31 loss in 3Q 2022)

Consensus revenue estimates increase by 130%

New minor risk - Market cap size

HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051

Healios K.K. to Report Q3, 2023 Results on Nov 14, 2023

HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia

Price target increased by 11% to JP¥845

Second quarter 2023 earnings released: JP¥10.37 loss per share (vs JP¥32.62 loss in 2Q 2022)

Healios K.K. Announces Use of 3D Bioreactor-Based Manufacturing Method Produced Product for ARDS

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Healios K.K. to Report Q2, 2023 Results on Aug 14, 2023

Healios K.K. Announces Submission of Clinical Trial Notification for RPE Tail Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

First quarter 2023 earnings released: JP¥11.52 loss per share (vs JP¥26.47 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to JP¥60.13 loss

Price target decreased by 19% to JP¥762

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Healios K.K. Announces Management Changes

Forecast to breakeven in 2025

High number of new directors

Healios K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: JP¥12.31 loss per share (vs JP¥34.86 loss in 3Q 2021)

Healios K.K. announced that it has received ¥100.0316 million in funding from SATAKE Corporation

HEALIOS Announces Results from the TREASURE Study

Healios K.K. announced that it expects to receive ¥100.0316 million in funding from SATAKE Corporation

Healios K.K. NK Cells Demonstrate Anti-Tumor Effect in Lung Cancer Patient-Derived Cancer Organoids

Healios K.K. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

First half 2022 earnings released: JP¥59.11 loss per share (vs JP¥36.60 loss in 1H 2021)

Healios K.K. to Report Q2, 2022 Results on Aug 10, 2022

Healios K.K. Reports Top-Line Results from Treasure Study for Ischemic Stroke

First quarter 2022 earnings released: JP¥26.47 loss per share (vs JP¥19.92 loss in 1Q 2021)

Price target decreased to JP¥2,760

Less than half of directors are independent

Healios K.K. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to JP¥2,760

Healios K.K. Announces Completion of 365 Days Post-Administration Follow Up for TREASURE Study for Patients with Ischemic Stroke

Healios K.K. Provides Progress Update in Relation to Application for Approval for HLCM051 for ARDS

Full year 2021 earnings released: JP¥93.36 loss per share (vs JP¥107 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Healios K.K., Annual General Meeting, Mar 25, 2022

Healios K.K. Announces Announcement of Change in Management

Third quarter 2021 earnings released: JP¥34.78 loss per share (vs JP¥29.02 loss in 3Q 2020)

HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study

First quarter 2021 earnings released: JP¥19.92 loss per share (vs JP¥29.02 loss in 1Q 2020)